| Q35640730 | "Cocktail" approaches and strategies in drug development: valuable tool or flawed science? |
| Q34122414 | Antiarrhythmic agents: drug interactions of clinical significance |
| Q36720920 | Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach |
| Q40648534 | Assessment of liver metabolic function. Clinical implications |
| Q77452375 | Clinical pharmacokinetics of nisoldipine coat-core |
| Q72280929 | Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes |
| Q73185409 | Dietary salt increases first-pass elimination of oral quinidine |
| Q73228890 | Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4 |
| Q58817150 | Effect of liver disease on dose optimization |
| Q34296874 | Health risks of herbal remedies |
| Q44247783 | Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment |
| Q73511084 | Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol |
| Q36055046 | Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes |
| Q34409085 | The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin |
| Q40929413 | Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir |
| Q73846452 | Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes |
| Q30778435 | Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? |